• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles 2018
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles 2018
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Mattingly, II, T.J.
    Levy, J.F.
    Slejko, J.F.
    Date
    2018
    Journal
    PharmacoEconomics
    Publisher
    Springer International Publishing
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://dx.doi.org/10.1007/s40273-018-0667-9
    Abstract
    Background: Drug costs are frequently estimated in economic analyses using wholesale acquisition cost (WAC), but what is the best approach to develop these estimates? Pharmaceutical manufacturers recently released transparency reports disclosing net price increases after accounting for rebates and other discounts. Objective: Our objective was to determine whether manufacturer net prices (MNPs) could approximate the discounted prices observed by the U.S. Department of Veterans Affairs (VA). Methods: We compared the annual, average price discounts voluntarily reported by three pharmaceutical manufacturers with the VA price for specific products from each company. The top 10 drugs by total sales reported from company tax filings for 2016 were included. The discount observed by the VA was determined from each drug's list price, reported as WAC, in 2016. Descriptive statistics were calculated for the VA discount observed and a weighted price index was calculated using the lowest price to the VA (Weighted VA Index), which was compared with the manufacturer index. Results: The discounted price as a percentage of the WAC ranged from 9 to 74%. All three indexes estimated by the average discount to the VA were at or below the manufacturer indexes (42 vs. 50% for Eli Lilly, 56 vs. 65% for Johnson & Johnson, and 59 vs. 59% for Merck). Conclusions: Manufacturer-reported average net prices may provide a close approximation of the average discounted price granted to the VA, suggesting they may be a useful proxy for the true pharmacy benefits manager (PBM) or payer cost. However, individual discounts for products have wide variation, making a standard discount adjustment across multiple products less acceptable. Copyright 2018, The Author(s).
    Keyword
    pharmaceutical manufacturers
    price discounts
    United States. Department of Veterans Affairs
    Drug Costs
    Identifier to cite or link to this item
    https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046788845&doi=10.1007%2fs40273-018-0667-9&partnerID=40&md5=e88245b7a70753a81b8d9cd8ded11691; http://hdl.handle.net/10713/9142
    ae974a485f413a2113503eed53cd6c53
    10.1007/s40273-018-0667-9
    Scopus Count
    Collections
    UMB Open Access Articles 2018

    entitlement

    Related articles

    • Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    • Authors: Dickson S, Reynolds I
    • Issue date: 2019 Jul 3
    • Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
    • Authors: Hernandez I, San-Juan-Rodriguez A, Good CB, Gellad WF
    • Issue date: 2020 Mar 3
    • Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
    • Authors: Berkemeier F, Whaley C, Robinson JC
    • Issue date: 2019 Dec
    • A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses.
    • Authors: Levy J, Rosenberg M, Vanness D
    • Issue date: 2018 Jun
    • Specialty Drug Price Trends in the Federal 340B Drug Discount Program.
    • Authors: Lee CH, Chang J, McCombs J
    • Issue date: 2019 Feb
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.